|
|
Bradley T. Messmer, Davorka Messmer, Steven L. Allen, Jonathan E. Kolitz, Prasad Kudalkar, Denise Cesar, Elizabeth J. Murphy, Prasad Koduru, Manlio Ferrarini, Simona Zupo, Giovanna Cutrona, Rajendra N. Damle, Tarun Wasil, Kanti R. Rai, Marc K. Hellerstein, Nicholas Chiorazzi
J Clin Invest. 2005;
115(3):755
doi:10.1172/JCI23409
Abstract |
Full text
| PDF
| Supplemental material

D
ue to its relatively slow clinical progression, B cell chronic lymphocytic leukemia (B-CLL) is classically described as a disease of accumulation rather than proliferation. However, evidence for various forms of clonal evolution suggests that B-CLL clones may be more dynamic than previously assumed. We used a nonradioactive, stable isotopic labeling method to measure B-CLL cell kinetics in vivo. Nineteen patients drank an aliquot of deuterated water (2H2O) daily for 84 days, and 2H incorporation into the deoxyribose moiety of DNA of newly divided B-CLL cells was measured by gas chromatography/mass spectrometry, during and after the labeling period. Birth rates were calculated from the kinetic profiles. Death rates were defined as the difference between calculated birth and growth rates. These analyses demonstrated that the leukemic cells of each patient had definable and often substantial birth rates, varying from 0.1% to greater than 1.0% of the entire clone per day. Those patients with birth rates greater than 0.35% per day were much more likely to exhibit active or to develop progressive disease than those with lower birth rates Thus, B-CLL is not a static disease that results simply from accumulation of long-lived lymphocytes. Rather, it is a dynamic process composed also of cells that proliferate and die, often at appreciable levels. The extent to which this turnover occurs has not been previously appreciated. A correlation between birth rates and disease activity and progression appears to exist, which may help identify patients at risk for worsening disease in advance of clinical deterioration.
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal.
Not all publishers participate in CrossRef, so this information is not comprehensive.
Additionally, data may not reflect the most current citations to this article,
and the data may differ from citation information available from other sources
(for example, Google Scholar, Web of Science, and Scopus).
Total citations by year
in CrossRef
Citations to this article
in CrossRef
(75)
| Title and authors |
Publication |
Year |
Telomeric damage in early stage of chronic lymphocytic leukemia correlates with shelterin dysregulation
A. Augereau, C. T'kint de Roodenbeke, T. Simonet, S. Bauwens, B. Horard, M. Callanan, D. Leroux, L. Jallades, G. Salles, E. Gilson, D. Poncet
|
Blood
|
2011 |
Silencing of the inhibitor of DNA binding protein 4 (ID4) contributes to the pathogenesis of mouse and human CLL.
Shih-Shih Chen, Rainer Claus, David M Lucas, Lianbo Yu, Jiang Qian, Amy S Ruppert, Derek A West, Katie E Williams, Amy J Johnson, Fred Sablitzky, Christoph Plass, John C Byrd
|
Blood
|
2011 |
Treatment of chronic lymphocytic leukemia requires targeting of the protective lymph node environment with novel therapeutic approaches
Rachel E Hayden, Guy Pratt, Claudia Roberts, Mark T Drayson, Chris M Bunce
|
Leuk Lymphoma
|
2011 |
Laser microdissection for the assessment of the clonal relationship between chronic lymphocytic leukemia/small lymphocytic lymphoma and proliferating B cells within lymph node pseudofollicles
M L Vandewoestyne, V C Pede, K Y Lambein, M F Dhaenens, F C Offner, M M Praet, J J Philippé, T J Kipps, D L Deforce
|
Leukemia
|
2011 |
Sorafenib induces cell death in chronic lymphocytic leukemia by translational downregulation of Mcl-1
S Huber, M Oelsner, T Decker, C Meyer zum Büschenfelde, M Wagner, G Lutzny, T Kuhnt, B Schmidt, R A J Oostendorp, C Peschel, I Ringshausen
|
Leukemia
|
2011 |
Non-malignant B cells and chronic lymphocytic leukemia cells induce a pro-survival phenotype in CD14+ cells from peripheral blood
N Bhattacharya, S Diener, I S Idler, T F Barth, J Rauen, A Habermann, T Zenz, P Möller, H Döhner, S Stilgenbauer, D Mertens
|
Leukemia
|
2011 |
Clonal evolution including 14q32/IGHtranslocations in chronic lymphocytic leukemia: analysis of clinicobiologic correlations in 105 patients
Francesco Cavazzini, Lara Rizzotto, Olga Sofritti, Giulia Daghia, Francesca Cibien, Sara Martinelli, Maria Ciccone, Elena Saccenti, Melissa Dabusti, Abbas Awad Elkareem, Antonella Bardi, Elisa Tammiso, Antonio Cuneo, Gian Matteo Rigolin
|
Leuk Lymphoma
|
2011 |
CD38 and chronic lymphocytic leukemia: a decade later
F. Malavasi, S. Deaglio, R. Damle, G. Cutrona, M. Ferrarini, N. Chiorazzi
|
Blood
|
2011 |
The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia
J. Hoellenriegel, S. A. Meadows, M. Sivina, W. G. Wierda, H. Kantarjian, M. J. Keating, N. Giese, S. O'Brien, A. Yu, L. L. Miller, B. J. Lannutti, J. A. Burger
|
Blood
|
2011 |
Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765
S. E. M. Herman, A. L. Gordon, E. Hertlein, A. Ramanunni, X. Zhang, S. Jaglowski, J. Flynn, J. Jones, K. A. Blum, J. J. Buggy, A. Hamdy, A. J. Johnson, J. C. Byrd
|
Blood
|
2011 |
|